BioNTech
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline in...
Latest News
4 days ago · barrons.com
BioNTech May Be the Next Moderna. Even if it Isn't, the Stock Is a Buy.BioNTech has multiple catalysts that could generate a rally of 35% for the stock.
5 days ago · fool.com
BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?BioNTech is aggressively pivoting its mRNA technology toward a deep pipeline of oncology treatments. Vertex Pharmaceuticals maintains high profitability and a dominant market share in cystic fibrosis therapies.
8 days ago · fool.com
BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era.BioNTech and Moderna are working to reduce their dependence on COVID-19 vaccines through expanding pipelines in cancer treatment and other diseases. Moderna's latest quarterly results showed improving financial performance, alongside promising Phase 3 data for its personalized cancer vaccine.
11 days ago · 247wallst.com
Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges HigherA quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.
11 days ago · fool.com
Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?Axsome Therapeutics is generating rapid revenue growth from its expanding portfolio of central nervous system treatments. BioNTech maintains a massive cash position and virtually no debt while shifting its focus toward oncology and mRNA innovation.
13 days ago · seekingalpha.com
BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade)BioNTech is rated Hold due to a narrowing pipeline, negative cash flow, and reliance on two main assets: pumitamig and gotistobart. Q3 profit is less meaningful than the widening gap between reported earnings and cash economics, with liquid assets declining despite reported net income. BNTX's revised revenue outlook reflects only a modest improvement, and ongoing cash burn, portfolio retrenchment, and pipeline concentration heighten risk.
13 days ago · seekingalpha.com
BioNTech SE (BNTX) Q3 2026 Earnings Call TranscriptBioNTech SE ( BNTX ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Douglas Maffei - Vice President of Strategy & Investor Relations Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Özlem Türeci - Co-Founder, Chief Medical Officer & Member of Management Board Ramón Zapata-Gomez - CFO & Member of Management Board Annemarie Hanekamp - Chief Commercial Officer & Member of Management Board Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Tazeen Ahmad - BofA Securities, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Cory Kasimov - Evercore Inc. Terence Flynn - Morgan Stanley, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Presentation Operator Welcome to BioNTech's Third Quarter 2026 Earnings Call. I will now hand the call over to Doug Maffei, Vice President of Investor Relations.
14 days ago · marketbeat.com
BioNTech Q3 Earnings Call HighlightsBioNTech NASDAQ: BNTX reported third-quarter 2026 revenue of €1.3 billion, down from €1.5 billion a year earlier, as lower demand for its COVID-19 vaccine weighed on results. The company raised the midpoint of its full-year revenue outlook while highlighting progress across its late-stage oncology pipeline, including lung cancer, breast cancer and mRNA cancer immunotherapy programs.
14 days ago · globenewswire.com
BioNTech Announces Third Quarter 2026 Financial Results and Corporate UpdateDelivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecan Advanced the first global Phase 3 clinical trial to evaluate pumitamig in combination with Gilead's TROP2-directed antibody-drug conjugate sacituzumab govitecan in triple-negative breast cancer, pending regulatory approval Presented data demonstrating gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer Launched variant-adapted COVID-19 vaccine for the 2026/2027 vaccination season in multiple regions worldwide Third quarter 2026 revenues of €1,289.2 million1 , adjusted2 R&D expenses of €578.5 million (IFRS R&D expenses of €748.1 million), and adjusted SG&A3 expenses of €178.5 million Raised full-year 2026 revenue guidance midpoint and updated range to €1.7–1.9 billion, and maintained strong financial position with cash, cash equivalents and security investments of €16.2 billion4 Conference call and webcast scheduled for November 3, 2026, at 8:00 a.m. EST (2:00 p.m.
20 days ago · 247wallst.com
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge HigherShrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock stands at $217, up 4% this morning.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove BNTX